AstraZeneca: FDA Approves Tagrisso for Lung Cancer
March 31 2017 - 2:46AM
Dow Jones News
By Razak Musah Baba
LONDON--AstraZeneca PLC's (AZN.LN) lung cancer drug Tagrisso has
been granted full approval by the U.S. Food and Drug
Administration.
AstraZeneca said Friday that the FDA has granted approval for
Tagrisso (osimertinib) 80 milligram once-daily tablets, for the
treatment of patients with metastatic epidermal growth factor
receptor T790M mutation-positive non-small cell lung cancer.
Tagrisso is the first and only approved medicine in the U.S.
Also Friday, the biopharmaceutical said it has completed the
agreement with TerSera Therapeutics LLC for the commercial rights
to Zoladex in the U.S. and Canada.
In February AstraZeneca announced a deal giving TerSera
commercial rights to its prostate cancer treatment Zoladex in the
U.S. and Canada.
AstraZeneca said Friday it has received a payment of $250
million from TerSera for the commercial rights to the medicine.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
(END) Dow Jones Newswires
March 31, 2017 02:31 ET (06:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
